-

GE HealthCare named to 2025 Fortune World’s Most Admired Companies list

  • This is GE HealthCare’s first appearance on the list, marking a significant milestone as an independent company

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has been named to 2025 Fortune World’s Most Admired Companies™ list. The company has been recognized across several categories including the quality of management, products and services, innovation, value as a long-term investment, financial soundness, talent acquisition and retention, community and environmental responsibility, global business, and use of corporate assets.

Being named to Fortune World’s Most Admired Companies™ list for the first time, two years after becoming an independent company, is a testament to GE HealthCare’s progress against its precision care strategy across disease states, enabling colleagues to deliver innovations that improve clinical workflows and help clinicians make more precise diagnoses and improve patient outcomes.

“This recognition is a testament to the dedication of our 51,000 global colleagues who help deliver our precision care strategy to best serve our patients and customers,” said Peter Arduini, President and CEO at GE HealthCare. “Our entrepreneurial and inclusive culture ensures that the broad perspectives and expertise of our teams continue to build our 125-year legacy of innovation, advance our purpose-driven strategy and help make a meaningful impact on healthcare worldwide.”

A company's score must rank in the top half of its industry survey to be listed. The ranking is considered the “gold standard” for employee-centric companies, highlighting employers who have created an exemplary work environment. For more information and to view the complete list of companies, visit: http://fortune.com/worlds-most-admired-companies/.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.

Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

From Fortune, ©2025 Fortune Media IP Limited. All rights reserved. Used under license. Fortune is a registered trademark and Fortune World’s Most Admired Companies™ is a trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse the products or services of GE HealthCare.

Contacts

GE HealthCare Media Contact:
Jennifer Fox
(414) 530-3027
jennifer.r.fox@gehealthcare.com

GE HealthCare

NASDAQ:GEHC

Release Versions

Contacts

GE HealthCare Media Contact:
Jennifer Fox
(414) 530-3027
jennifer.r.fox@gehealthcare.com

More News From GE HealthCare

GE HealthCare announces lead industrial role in largest EU-funded IHI consortium to advance cardio-oncology care across Europe

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced its leading industrial role in the new COMPASS consortium, a five-year initiative focused on improving precision cardio-oncology care and advancing early detection of cardiovascular risks in cancer patients across Europe. COMPASS combines clinical excellence with novel healthcare technology, and with a total budget of €50.5 million and more than sixty partners, it is one of the largest public-private partnerships under the I...

GE HealthCare to showcase comprehensive cardiology portfolio at ACC.26, including its latest AI-enabled imaging technologies, advanced software solutions, and key collaborations

CHICAGO--(BUSINESS WIRE)--At ACC.26, GE HealthCare (Nasdaq: GEHC) will showcase some of its boldest ideas yet that support clinicians across the cardiology care pathway - from diagnosis to treatment to procedural guidance and monitoring. Its latest cardiology innovations, featuring advancements within diagnostic cardiology, CT, image guiding solutions, ultrasound, cloud, and software solutions, are helping clinicians deliver critical precision care throughout the patient journey. According to t...

GE HealthCare’s Photonova Spectra photon-counting CT receives FDA clearance

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Photonova™ Spectra,i an innovative photon‑counting computed tomography (PCCT) solution powered by the company’s novel Deep Silicon detector technology and offered as a flexible platform with multiple configurations to meet diverse clinical needs. With wide coverage and the combination of ultra-high definition (UHD) spatial and spectral imaging, Photonova Spec...
Back to Newsroom